BIOMARIN PHAR. DL-,001 | 66.28 |
Date/Time | 02/23 / 17:35 |
Chg. / Chg.(%) | - / |
Bid | - |
Ask | - |
Open | 66.28 |
Previous Close | 67.21 |
High | 66.28 |
Low | 66.28 |
Volume [EUR] | 0.00 |
Volume [Units] | 0 |
Price fixings | 1 |
ISIN | US09061G1013 |
Security | BM8 |
Exchange | Xetra |
Type | Stock |
Exchange | Last | Volume | |
---|---|---|---|
NASDAQ | 83.3200 | ![]() |
1,040,287 |
IEX | 83.34 | ![]() |
52,155 |
Cboe US | 83.32 | ![]() |
49,041 |
TradeGate | 68.330 | ![]() |
370 |
London Inter.. | 84.15 | ![]() |
186 |
Stuttgart | 69.320 | ![]() |
150 |
Vienna Globa.. | 69.02 | ![]() |
148 |
gettex | 68.530 | ![]() |
16 |
Frankfurt | 67.1800 | ![]() |
0 |
Berlin | 67.49 | ![]() |
0 |
München | 67.17 | ![]() |
0 |
Düsseldorf | 67.60 | ![]() |
0 |
Lang & Schwa.. | 67.48 | ![]() |
|
Mexico | 1,691.41 | ![]() |
100 |
Xetra | 66.28 | 0 |
News
- BioMarin sinks 32% as FDA delays its hemophilia treatment
08/19/2020 / 16:23 - TeleTrader - Nasdaq turns red as pharma stocks fall
04/28/2020 / 16:48 - TeleTrader - BioMarin Enrolls First Participant in Phase 3 Trial of Vosoritide for Treatment of Children with Achondroplasia
12/12/2016 / 14:29 - GlobeNewswire - NICE Recommends BioMarin's Vimizim® (elosulfase alfa) for the Treatment of Morquio A Syndrome in England
11/23/2015 / 16:59 - GlobeNewswire